what's the highest dose of semaglutide for weight loss obesity treatment landscape continues to evolve. A higher-dose version (Wegovy 7.2 mg) has recently been studied and approved, based on large clinical trials showing additional compared to Increasing semaglutide dose showed very

To avoid the requirement for subcutaneous injections and new formulations of semaglutide have been developed

The provision of options to upload progress photographs may mitigate this but does not eliminate the issue

When combined with a recommended diet and exercise plan patient will lower their risk of having a heart attack or stroke in the next 10 years

Key FDA guidance: Incremental weight loss (enobosarm + GLP-1 versus GLP-1 alone) is an acceptable primary endpoint for approval The 3 mg dose is appropriate for continued development FDA encouraged including younger patients, not just older populations Phase 2 QUALITY study data: 16 weeks of enobosarm in older patients taking semaglutide Preserved lean mass and burned additional fat mass Improved physical function During the maintenance period (12 weeks after semaglutide discontinuation), enobosarm prevented weight regain by 46% compared to placebo Next steps : Veru plans to initiate the Phase 2b PLATEAU trial in Q1 2026, enrolling approximately 180 patients (both older and younger) with obesity taking tirzepatide